亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

蘇州全輝生物科技有限公司  

醫藥原料及中間體生產銷售

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:劉才伙
  • 電話:0512-66368265
  • 郵件:contact@szqhbio.com
  • 傳真:0512-66368287
  • QQ:1259679610
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > ***吡格列酮 CAS號:112529-15-4
***吡格列酮 CAS號:112529-15-4
單價 面議對比
詢價 暫無
發貨 江蘇蘇州市付款后3天內
品牌 蘇州全輝
過期 長期有效
更新 2016-02-17 09:26
 
詳細信息
 

***吡格列酮

產品名稱:***吡格列酮

化學名稱:(±)5-{4-[2-(5-乙基-2-吡啶基)乙氧基]苯甲基}-2,4-噻唑烷二酮***

英文:Pioglitazone Hydrochloride

分子式:C19H20N2O3S•HCl

分子量:392.89

CAS號:112529-15-4

質量標準:企業標準/WS1 (X 051) 2006Z/CP2010

性狀:白色或類白色結晶狀粉末,無臭,溶解于甲醇,不溶于水

有關物質:不得過1.0%

干燥失重:不得過0.5%

灼燒殘渣:不得過0.1%

重金屬:不得過百萬分之二十

含量:98.0%~102.0%

熔點:193 194℃

包裝:25kg;紙板桶/按客戶要求包裝

用途:***吡格列酮可與飲食控制和體育鍛煉聯合以改善和控制血糖,是最新的治療II型糖尿病藥,副作用小。

聯系方式:銷售陳:0512-6636826518994391946QQ1259679610contact@szqhbio.*

©2025 蘇州全輝生物科技有限公司 版權所有   技術支持:化工網   訪問量:4829  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |